Revenue growth strong; disposal of non-core businesses hurt profit
Peptide business becoming a new growth driver
Solid results: strong revenue growth and improving asset quality
Accelerating revenue growth in 2H17, cash flow to remain strong
22Q1营收净利高增,淡季不淡,全年业绩可期